Literature DB >> 15458610

A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder.

Robert M A Hirschfeld1, Siegfried Kasper.   

Abstract

Bipolar disorder is a recurrent lifelong condition associated with significant morbidity and mortality. The main goals of treatment are the acute management of manic/depressive episodes and the prevention of recurrence. Mood stabilizers are the basis of most treatment regimens. Although lithium is the classical mood stabilizer, dissatisfaction with its efficacy and tolerability has led to increased use of other mood- stabilizing agents, including anticonvulsants. Newer anticonvulsants such as oxcarbazepine may offer improved tolerability and fewer drug-drug interactions compared to older drugs like carbamazepine. A search of the literature shows that data from controlled clinical studies support the efficacy of carbamazepine in treating acute mania and as maintenance therapy. In addition, a growing body of data for oxcarbazepine suggests that this newer agent may have a similar efficacy profile to carbamazepine, with improved tolerability. This review presents a balanced selection of the key studies on carbamazepine and oxcarbazepine in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458610     DOI: 10.1017/S1461145704004651

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  10 in total

Review 1.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

2.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

3.  Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.

Authors:  Jessica F Douglas; Kevin B Sanders; M Hannah Benneyworth; Jessica L Smith; Virginia M Dejean; Susan G McGrew; Jeremy Veenstra-Vanderweele
Journal:  J Autism Dev Disord       Date:  2013-05

Review 4.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Synthesis of heterocycles via Pd-ligand controlled cyclization of 2-chloro-N-(2-vinyl)aniline: preparation of carbazoles, indoles, dibenzazepines, and acridines.

Authors:  Dmitry Tsvelikhovsky; Stephen L Buchwald
Journal:  J Am Chem Soc       Date:  2010-10-13       Impact factor: 15.419

Review 6.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Excess mortality in bipolar disorders.

Authors:  Christopher Miller; Mark S Bauer
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

8.  Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior.

Authors:  Christopher J Miller; Mingfei Li; Robert B Penfold; Austin F Lee; Eric G Smith; David N Osser; Laura Bajor; Mark S Bauer
Journal:  BMC Psychiatry       Date:  2014-11-30       Impact factor: 3.630

9.  Patient Survival After Acute Voluntary Poisoning With a Huge Dose of Oxcarbazepine and Olanzapine.

Authors:  Vasiliki Kalogera; Dimitrios Galopoulos; Gerasimos Eleftheriotis; Evangelia Meimeti; Ioannis Malios; Georgios Marathonitis; Chariclia Loupa
Journal:  Med Arch       Date:  2018-10

10.  Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report.

Authors:  Panagiotis Oulis; Evangelos Karapoulios; Anastasios V Kouzoupis; Vasilios G Masdrakis; Konstantinos A Kontoangelos; Konstantinos Makrilakis; Nikolaos A Karakatsanis; Charalambos Papageorgiou; Nikolaos Katsilambros; Constantin R Soldatos
Journal:  Ann Gen Psychiatry       Date:  2007-10-08       Impact factor: 3.455

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.